Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients

Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in precli...

Descripción completa

Detalles Bibliográficos
Autores principales: Boydell, Emma, Marinari, Eliana, Migliorini, Denis, Dietrich, Pierre-Yves, Patrikidou, Anna, Dutoit, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520681/
https://www.ncbi.nlm.nih.gov/pubmed/30986995
http://dx.doi.org/10.3390/cancers11040464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520681/
https://www.ncbi.nlm.nih.gov/pubmed/30986995
http://dx.doi.org/10.3390/cancers11040464

Ejemplares similares